39 results about "Convection-Enhanced Delivery" patented technology

A step-design cannula and delivery system for chronic delivery of therapeutic substances into the brain using convention-enhanced delivery of therapeutic substances and which effectively prevents reflux in vivo and maximizes distribution in the brain.

A method is provided for delivering a therapeutic agent to selected sites within an organism. More particularly, the invention allows for the simultaneous delivery of therapeutics to multiple treatment locations from a single catheter using a single pumping source. The catheter utilizes a microporous membrane that allows for the distribution of therapeutic agents from multiple longitudinal positions.

Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.

An apparatus and system is provided for delivering a therapeutic agent to selected sites within an organism. More particularly, the invention allows for the simultaneous delivery of therapeutics to multiple treatment locations from a single catheter using a single pumping source. The catheter utilizes a microporous membrane that allows for the distribution of therapeutic agents from multiple longitudinal positions.

A method for monitoring and controlling convection enhanced delivery of a therapeutic agent to a target tissue is disclosed. A tracer that is detectable, for example, by magnetic resonance imaging (MRI) and/or by X-ray computed tomography (CT) is co-infulsed with the therapeutic agent and used to monitor the distribution of the therapeutic agent as it moves through the target tissue. The images obtained during delivery are used to confirm delivery of the therapeutic agent to the target tissue and to avoid exposure of tissue outside of the targeted area to the therapeutic agent. In addition, the signal intensity of the images may be used to confirm that the therapeutic agent has been delivered to the target tissue at a desired concentration.

A method of treating tumors that express a receptor for IL-13 is disclosed. The method involves directly introducing into the tumor a cytotoxin that targets the IL-13 receptor. The cytotoxic agent can be introduced by convection-enhanced delivery through a suitable catheter or by other means. Where a convection-enhanced catheter is employed, the method involves positioning the tip of a catheter at least in close proximity to the tumor. After the catheter is positioned, it is connected to a pump which delivers the active agent through the catheter tip to the tumor. A pressure gradient from the tip of the catheter is maintained during infusion.

A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.

A primable catheter including a thermoreactive, viscoelastic material that is internally supported with a trocar wire. The primable catheter further includes a multi-chamfered tip and a gap interposed between an inner surface of the catheter and the outer surface of the trocar, such that a priming fluid is permitted to flow through the catheter and purge air trapped between the trocar and the inner surface of the catheter. Following insertion of the catheter, the trocar is removed and a therapeutic is infused via the catheter.

The invention provides methods for treating neurological disorders, which involve administering therapeutic agents to the thalamus by convection enhanced delivery.

A chemotherapy agent or a pharmaceutical composition including chemotherapy agent and artificial cerebrospinal fluid, wherein the chemotherapy agent at a concentration of between 0.01 mg/ml and 0.7 mg/ml for use in the treatment of brain cancer and a method of treating a glioma including administering a chemotherapy agent via convection enhanced delivery

A synergistic therapeutic effect is obtained in CNS cancer patients treated concomitantly with a first antineoplastic agent and a second antineoplastic agent, wherein one or both antineoplastic agents are administered by convection enhanced delivery. Combinations of interest include, without limitation, CED delivery of a topoisomerase inhibitor, e.g., topotecan, and systemic delivery of a triazene, e.g. temozolomide.

Methods for delivering a therapeutic agent to a cerebral cortex or to the cerebral cortex and spinal cord include administering a viral vector that includes the therapeutic agent into white matter of a brain in order to deliver the therapeutic agent to the cerebral cortex or to the cerebral cortex and spinal cord. Kits for performing such methods may include at least one viral vector, at least one therapeutic agent, and a convection enhanced delivery (CED) catheter.